Molecular Profiling Tests for making Adjuvant Chemotherapy Decisions
This information was originally presented at the NCCN 20th Annual Conference: Advancing the Standard of Cancer Care™ held in Hollywood, Florida.
This activity is designed to meet the educational needs of oncologists, nurses, and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Select and interpret molecular profiling tests for risk assessment to guide treatment decisions in early hormone receptor-positive (HR+) breast cancer
Amy Cyr, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support.
The faculty listed below has no relevant financial relationships to disclose:
Amy Cyr, MD
NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial interests to disclose:
Robert W. Carlson, MD; Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Shannon Scarinci; Jennifer McCann Weckesser
The activity planning staff listed below has disclosed the following relevant financial relationships:
AstraZeneca: Equity Interest/Stock Options
The NCCN clinical information team listed below, who has reviewed content, has no relevant financial relationships to disclose:
Rashmi Kumar, PhD; Dorothy Shead, MS
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Continuing education credit and contact hours are not available for this learning activity.